The company's flagship product, the PassPort patch, utilizes thermal energy to create tiny channels in the skin, enabling the delivery of various substances such as proteins, peptides, carbohydrates, and small molecules without the need for needles. In addition to this breakthrough technology, Altea Therapeutics also offers the Transdermal vaccine patch, which efficiently delivers water-soluble drugs and proteins. Their product portfolio includes disease prevention solutions, an insulin skin patch as an alternative to injections, and opioid patches with built-in deterrent layers. Founded in 1998 and based in Atlanta, Georgia, Altea Therapeutics operates as a subsidiary of Nitto Denko Corp since May 9, 2012.